Tschen E, Elewski B, Gorsulowsky D C, Pariser D M
Department of Dermatology, University of New Mexico School of Medicine, Albuquerque, USA.
J Am Acad Dermatol. 1997 Feb;36(2 Pt 1):S9-14. doi: 10.1016/s0190-9622(97)70316-5.
Butenafine hydrochloride, a potent new benzylamine with fungicidal activity, has been extensively studied and approved for topical use in Japan. Results reported here are from one of the first major North American butenafine clinical trials.
We evaluated butenafine in the treatment of tinea pedis in a controlled, randomized, double-blind trial.
Of 80 patients with positive fungal cultures, 40 applied butenafine 1% cream and 40 applied vehicle to the affected area once daily for 4 weeks. Efficacy was assessed during treatment and 4 weeks after.
Significantly more patients using butenafine than using vehicle had mycologic cure (butenafine, 88%; vehicle, 33%) and effective clinical response (butenafine, 78%; vehicle, 35%). Differences between treatment groups were greatest (p < 0.001) 4 weeks after treatment.
Butenafine applied once daily for 4 weeks resulted in an effective clinical response and mycologic cure of tinea pedis during treatment. Patients continued to improve for at least 4 weeks after treatment.
盐酸布替萘芬是一种具有杀菌活性的新型强效苄胺，已在日本进行了广泛研究并获批用于局部治疗。此处报告的结果来自北美首批主要的布替萘芬临床试验之一。
我们在一项对照、随机、双盲试验中评估了布替萘芬治疗足癣的效果。
80例真菌培养阳性的患者中，40例每天在患部涂抹1%布替萘芬乳膏，40例涂抹赋形剂，持续4周。在治疗期间及治疗后4周评估疗效。
使用布替萘芬的患者真菌学治愈率（布替萘芬组为88%；赋形剂组为33%）和有效临床反应率（布替萘芬组为78%；赋形剂组为35%）显著高于使用赋形剂的患者。治疗组之间的差异在治疗后4周最大（p < 0.001）。
每天涂抹一次布替萘芬，持续4周，在治疗期间可有效治疗足癣并实现真菌学治愈。治疗后患者至少持续改善4周。
